A first-in-human phase i study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors

Clinical Cancer Research

Volumn 21, Issue 6, 2015, Pages 1281-1288

  Diaz, Luis A ^a   Coughlin, Christina M ^b   Weil, Susan C ^b   Fishel, Jean ^b   Gounder, Mrinal M ^c   Lawrence, Susan ^a   Azad, Nilofer ^a   O'Shannessy, Daniel J ^b   Grasso, Luigi ^b   Wustner, Jason ^b   Ebel, Wolfgang ^b   Carvajal, Richard D ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Morphotek Inc   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; ENDOSIALIN; MONOCLONAL ANTIBODY; MORAB 004; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD248 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MORAB-004; TUMOR ANTIGEN;

ABDOMINAL PAIN; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANGIONEUROTIC EDEMA; ANTIBODY RESPONSE; ARTICLE; BACKACHE; BACTEREMIA; BODY WEIGHT DISORDER; CLINICAL ARTICLE; CONFUSION; CONSCIOUSNESS DISORDER; DIPLOPIA; DISEASE ACTIVITY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GASTROESOPHAGEAL REFLUX; HEMATOMA; HUMAN; HYDRONEPHROSIS; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; INFUSION RELATED REACTION; LEUKOPENIA; LIVER CELL CARCINOMA; MALE; MAXIMUM TOLERATED DOSE; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; PANCREATIC NEUROENDOCRINE TUMOR; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOGRAPHY; SARCOMA; SINUS TACHYCARDIA; SOLID TUMOR; SOMNOLENCE; SPEECH DISORDER; TREATMENT RESPONSE; URINARY TRACT INFECTION; URINE RETENTION; VAGINA BLEEDING; VOMITING; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG RESISTANCE; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; NEOPLASMS;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS;

EID: 84927607922     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1829     Document Type: Article

References (17)

1. St. Croix B, Rago C, Velculescu V, Traversos G, Romans KE, Montgomery E, et al. Genes expressed in human tumor endothelium. Science 2000;289:1197-202.
2. Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci 1992;89:10832-6.
3. Thomas WE. Brain macrophages: on the role of pericytes and perivascular cells. Brain Res Rev 1999;31:42-57.
4. Christian S, Winkler R, Helfrich I, Boos AM, Besemfelder E, Schadendorf D, et al. Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor-vessel associated mural cells. Am J Pathol 2008;172:486-94.
5. Rouleau C, Curiel M, Weber W, Smale R, Kurtzberg L, Mascarello J, et al. Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. Clin Cancer Res 2008;14: 7223-36.
6. Brady J, Neal J, Sadakar N, Gasque P. Human endosialin (tumor endothelial marker 1) is abundantly expressed in highlymalignant and invasive brain tumors. J Neuropathol Exp Neurol 2004;63:2374-83.
7. Rouleau C, Smale R, Fu Y-S, Hui G, Wang F, Hutto E, et al. Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling. Int J Oncol 2011;39:73-89.
8. Nanda A, Karim B, Peng Z, Liu G, Qiu W, Gan C, et al. Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors. Proc Natl Acad Sci 2006;103:3351-6.
9. Tomkowicz B, Rybinski K, Foley B, Ebel W, Kline B, Routhier E, et al. Interaction of endosialin/TEM-1 with extracellular matrix proteins mediates cell adhesion and migration. Proc Natl Acad Sci 2007;103:17965-70.
10. Maia M, DeVriese A, Janssens T, Moons M, Lories RJ, Tavernier J, et al. CD248 facilitates tumor growth via its cytoplasmic domain. BMC Cancer 2011;11:162.
11. Tomkowicz B, Rybinski K, Sebeck D, Sass P, Nicolaides NC, Grasso L, et al. Endosialin/TEM-1/CD248 regulates pericyte proliferation through PDGF receptor signaling. Cancer Biol Ther 2010;9:908-15.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan R, Rubenstein L, et al.Newguidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
13. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of nitrogen mustards in the palliative treatment of cancer. Cancer 1948;1:634-56.
14. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS. [database on the Internet] [cited 2006 Aug 9]. Available from: http://ctep.cancer.gov.
15. Bagley RG, Rouleau C, St. Martin T, Boutin P, Weber W, Ruzek M, et al. Human endosialin: precursor cells express tumor endothelial marker 1/endosialin/CD248. Mol Cancer Ther 2008;7:2536-46.
16. Bagley RG, Honma N, Weber W, Boutin P, Rouleau C, Shankara S, et al. Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization. Microvasc Res 2008;76:180-8.
17. Dolznig H, Schweifer N, Puri C, Kraut N, Rettig WJ, Kerjaschki D, et al. Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Immun 2005;5:10-8.